Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 91NCT00844298
• NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…Phase 3Results postedn = 455NCT01311687
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 20NCT04205409
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 78NCT03016871
• NOHARMIndependent statistical analysis of Novel Use Of Hydroxyurea in an African Region With Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01976416).Phase 3Results postedn = 208NCT01976416
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: primary endpoint…Phase 2Results postedn = 100NCT02098109
• Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 80NCT02962765
• NUCALA® Special Drug Use Investigation (EGPA, Long-term): Complete Statistical AnalysisIndependent statistical analysis of NUCALA® Special Drug Use Investigation (EGPA, Long-term): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03557060).Phase NAResults postedn = 4,115NCT03557060
• Obatoclax for Systemic Mastocytosis: Complete Statistical AnalysisIndependent statistical analysis of Obatoclax for Systemic Mastocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00918931).Phase 2Results postedn = 3NCT00918931
• Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine: Complete Statistical AnalysisIndependent statistical analysis of Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 1,083NCT01309269
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 49NCT01294579
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 36NCT01515176
• Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 12NCT01716208
• Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).Phase 2Results postedn = 4NCT01258933
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 99NCT01520922
• Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 72NCT03303339
• Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: Complete Statistical AnalysisIndependent statistical analysis of Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: primary endpoint results, effect estimate with…Phase 1Results postedn = 22NCT01971476
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 35NCT00950911
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 154NCT00509899
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…Phase 2Results postedn = 76NCT01565668
• Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 269NCT01722487
• Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 42NCT04434937
• Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 97NCT00920140
• Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: Complete Statistical AnalysisIndependent statistical analysis of Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 182NCT02519595
• Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD): Complete Statistical AnalysisIndependent statistical analysis of Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1NCT04371536
• Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): Complete Statistical AnalysisIndependent statistical analysis of Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 1NCT01090973
• ORCHARRDIndependent statistical analysis of Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 447NCT01014208
• ORIENT-1Independent statistical analysis of Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 96NCT03114683
• Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter’s Syndrome, Refractory CLL and PLL: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 48NCT00452374
• Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 17NCT02882321
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).Phase 2Results postedn = 3NCT02469415
• Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02588339).Phase 2Results postedn = 42NCT02588339
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 9NCT03256045
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 83NCT02506959
• PANORAMA_3Independent statistical analysis of Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02654990).Phase 2Results postedn = 248NCT02654990
• PARADIGM-2An independent statistical analysis of the randomized phase 3 PARADIGM-2 trial of nonacog beta pegol in patients with haemophilia B, including trial design, inhibitor endpoints, safety, planned statistical interpretation, and limitations.Phase 3Results postedn = 74NCT01333111
• Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 3NCT03988205
• PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05246670).Phase 2Results postedn = 88NCT05246670
• Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434330).Phase 2Results postedn = 91NCT00434330
• Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): Complete Statistical AnalysisIndependent statistical analysis of Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 244NCT00732641
• Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01758588).Phase 2Results postedn = 8NCT01758588
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 3NCT05191472
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 12NCT02767934
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 18NCT03401853
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 13NCT03506360
• Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).Phase 2Results postedn = 42NCT00496340
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 50NCT00546377
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 48NCT01912222
• Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01401010).Phase 4Results postedn = 12NCT01401010
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 112NCT01454076

← All therapeutic areas